Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2a Study of OPT-302 in Combination With Aflibercept for Persistent Central-involved Diabetic Macular Edema

Next Previous
X
Search
Trial Profile

Phase 1b/2a Study of OPT-302 in Combination With Aflibercept for Persistent Central-involved Diabetic Macular Edema

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary) ; Sozinibercept (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Opthea

    • Most Recent Events

    • 26 Nov 2020 Status changed from active, no longer recruiting to completed.
    • 17 Sep 2020 This trial has been completed in Latvia, according to European Clinical Trials Database record.
    • 27 Jul 2020 Results presented in an Opthea media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top